Intraperitoneal cisplatin with nanocis

PreclinicalSmall molecule

Intraperitoneal cisplatin with nanocis is one of 6 small molecule programs targeting Intraperitoneal Chemotherapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intraperitoneal ChemotherapyWithdrawn

Intraperitoneal ChemotherapyPreclinical

Withdrawn

Competition

Competitive Landscape

6 competitors in Intraperitoneal Chemotherapy

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

1 2

Camptosar

Pfizer

Phase 3

1 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 4

Sodium Thiosulfate

HHope Pharmaceuticals

Phase 2

1 5

Hyperthermic Intraperitoneal Chemotherapy

MMayo Clinic

Phase 2

1 6

Intraperitoneal cisplatin with nanocis

CCentre Jean Perrin

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intraperitoneal Chemotherapy1 trial

Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin

Withdrawn·CCentre Jean Perrin·N/A·NCT02667925

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intraperitoneal cisplatin with nanocis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intraperitoneal cisplatin with nanocis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intraperitoneal cisplatin with nanocis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Jean Perrin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentre Jean Perrin

Intraperitoneal cisplatin with nanocis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intraperitoneal Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News